文
论文分享
演练场
杂货铺
论文推荐
字
编辑器下载
登录
注册
C. Guyonneau
发表
213MO Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)
G. MacGrogan, H. Bonnefoi, O. Trédan, 2022, Annals of Oncology.